Expression of MicroRNAs associated with Gleason grading system in prostate cancer: MiR-182-5p is a useful marker for high grade prostate cancer

Prostate

Volumn 73, Issue 8, 2013, Pages 827-834

  Tsuchiyama, Katsuki ^a   Ito, Hideaki ^a   Taga, Minekatsu ^a   Naganuma, Seiji ^a   Oshinoya, Yukinosuke ^b   Nagano, Ken Ichi ^b   Yokoyama, Osamu ^a   Itoh, Hiroshi ^a  

^a UNIVERSITY OF FUKUI   (Japan)

^b Public Central Hospital of Matto Ishikawa   (Japan)

Author keywords

Gleason grading system; microdissection; microRNA; preoperative evaluation; prostate cancer

Indexed keywords

MICRORNA 182; MICRORNA 182 5P; MICRORNA 183 5P; MICRORNA 205; MICRORNA 205 5P; MICRORNA 221; MICRORNA 221 3P; MICRORNA 222 3P; MICRORNA 31; MICRORNA 34C 5P; MICRORNA 96 5P; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER STAGING; CONTROLLED STUDY; FEMALE; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MICRODISSECTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

AGED; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM GRADING; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM;

EID: 84876932851     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22626     Document Type: Article

References (31)

1. Fujimoto H, Nakanishi H, Miki T, Kubota Y, Takahashi S, Suzuki K, Kanayama HO, Mikami K, Homma Y,. Oncological outcomes of the prostate cancer patients registered in 2004 report from the cancer registration committee of the JUA. Int J Urol 2011; 18 (12): 876-881.
2. Damber JE, Aus G,. Prostate cancer. Lancet 2008; 371 (9625): 1710-1721.
3. D'Amico AV, Whittington R, Malkowicz SB, Fondurulia J, Chen MH, Kaplan I, Beard CJ, Tomaszewski JE, Renshaw AA, Wein A, Coleman CN,. Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol 1999; 17 (1): 168-172.
4. Coppla V, De Maria R, Bonci D,. MicroRNAs and prostate cancer. Endocr Relat Cancer 2010; 17 (1): F1-F17.
5. Loeb S, Catalona WJ,. Protate-specific antigen in clinical practice. Cancer Lett 2007; 249 (1): 30-39.
6. Rodriguez-Covarrubias F, Larre S, De La Taille A, Abbou CC, Salomon L,. The outcome of patients with pathological Gleason score > or = 8 prostate cancer after radical prostatectomy. BJU Int 2008; 101 (3): 305-307.
7. Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T,. Identification of novel genes coding for small expressed RNAs. Science 2001; 294 (5543): 853-858.
8. Bartel DP,. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116 (2): 281-297.
9. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Doening JR, Jacks T, Horvitz HR, Golub TR,. MicroRNA expression profiles classify human cancers. Nature 2005; 435 (7043): 834-838.
10. Tomaru Y, Hayashizaki Y,. Cancer research with non-coding RNA. Cancer Sci 2006; 97 (12): 1285-1290.
11. Calin GA, Croce CM,. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6 (11): 857-866.
12. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, Visakorpi T,. MicroRNA expression profiling in prostate cancer. Cancer Res 2007; 67 (13): 6230-6235.
13. Catto JWF, Alcaraz A, Bjartell AS, De Vere White R, Evans CP, Fussel S, Hamdy FC, Kallioniemi O, Mengual L, Schlomm T, Visakorpi T,. MicroRNA in prostate, bladder, and kidney cancer: A systematic review. Eur Urol 2011; 59 (5): 671-681.
14. Schaefer A, Jung M, Mollenkopf HJ, Wagner I, Stephan C, Jentzmik F, Miller K, Lein M, Kristiansen G, Jung K,. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer 2010; 126 (5): 1166-1176.
15. Wach S, Nolte E, Szczyrba J, Stöhr R, Hartmann A, Ømtoft T, Dyrskjøt L, Eltze E, Wieland W, Keck B, Ekici AB, Grässer F, Wullich B,. MicroRNA profiles of prostate carcinoma detected by multiplatform microRNA screening. Int J Cancer 2012; 130 (3): 611-621.
16. Wang L, Tang H, Thayanithy V, Subramanian S, Oberg AL, Cunningham JM, Cerhan JR, Steer CJ, Thibodeau SN,. Gene networks and microRNAs implicated in aggressive prostate cancer. Cancer Res 2009; 69 (24): 9490-9497.
17. Spahn M, Kneitz S, Scholz CJ, Stenger N, Rüdiger T, Ströbel P, Riedmiller H, Kneitz B,. Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence. Int J Cancer 2010; 127 (2): 394-403.
18. Martens-Uzunova ES, Jalava SE, Dits NF, van Leenders GJ, Møller S, Trapman J, Bangma CH, Litman T, Visakorpi T, Jenster G,. Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer. Oncogene 2012; 31 (8): 978-991.
19. Mihelich BL, Khramtsova EA, Arva N, Vaishnav A, Johnson DN, Giangreco AA, Martens-Uzunova E, Bagasra O, Kajdacsy-Balla A, Nonn L,. miR-183-96-182 cluster is overexpressed in prostate tissue and regulates zinc homeostasis in prostate cells. J Biol Chem 2011; 286 (52): 44503-44511.
20. Liu Z, Liu J, Segura MF, Shao C, Lee P, Gong Y, Hemando E, Wei JJ,. MiR 182 overexpression in tumorigenesis of high-grade ovarian papillary serous carcinoma. J Pathol 2012; 228 (2): 204-215.
21. Moskwa P, Buffa FM, Pan Y, Panchakshari R, Gottipati P, Muschel RJ, Beech J, Kulshrestha R, Abdelmohsen K, Weinstock DM, Gorospe M, Harris AL, Helleday T, Chowdhury D,. miR-182-mediated down-regulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. Mol Cell 2011; 41 (2): 210220.
22. Zhu W, Liu XG, He YJ, Chen DD, Hunag YY, Zhang YK,. Overexpression of members of the microRNA-183 family is a risk factor for lung cancer: A case control study. BMC Cancer 2011; 11: 393.
23. Yu J, Li A, Hong SM, Hruban RH, Goggins M,. MicroRNA alterations of pancreatic intraepithelial neoplasias. Clin Cancer Res 2012; 18 (4): 981-992.
24. Kong WQ, Bai R, Liu T, Cai CL, Liu M, Li X, Tang H,. MicroRNA-182 targets cyclic adenosine monophosphate responsive element binding protein 1 (CREB1) and suppresses cell growth in human gastric adenocarcinoma. FEBS J 2012; 279 (7): 1252-1260.
25. Guo J, Miao Y, Xiao B, Huan R, Jiang Z, Meng D, Wang Y,. Differential expression of microRNA species in human gastric cancer versus non-tumorous tissues. J Gastroenterol Hepatol 2009; 24 (4): 652-657.
26. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y, Goodall GJ,. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008; 10 (5): 593-601.
27. Iorio MV, Casalini P, Piovan C, Di Leva G, Merlo A, Triulzi T, Ménard S, Croce CM, Tagliabue E,. microRNA-205 regulates HER3 in human breast cancer. Cancer Res 2009; 69 (6): 2195-2200.
28. Gandellini P, Folini M, Longoni N, Pennati M, Binda M, Colecchia M, Salvioni R, Supino R, Moretti R, Limonta P, Valdagni R, Daidone MG, Zaffaroni N,. miR-205 exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cepsilon. Cancer Res 2009; 69 (6): 2287-2295.
29. Mercatelli N, Coppola V, Bonci D, Miele F, Costantini A, Guadagnoli M, Bonanno E, Muto G, Frajese GV, De Maria R, Spagnoli LG, Farace MG, Ciafrè SA,. The inhibition of the highly expressed miR-221 and miR-222 impairs the growth of prostate carcinoma xenografts in mice. PLoS ONE 2008; 3 (12): e4029.
30. Hagman Z, Larne O,., Edsjö A,., Bjartell A,., Ehmström RA,., Ulmert D,., Lilja H,., Ceder Y,. miR-34c is down regulated in prostate cancer and exerts tumor suppressive functions. Int J Cancer 2010; 127 (12): 2768-2776.
31. Brase JC, Johannes M, Schlomm T, Fälth M, Haese A, Steuber T, Beissbarth T, Kuner R, Sültmann H,. Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer 2011; 128 (3): 608-616.